Try our beta test site
168 studies found for:    Open Studies | Lymphoma OR CLL | t-cell therapy
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
Conditions: B-Cell Chronic Lymphocytic Leukemia;   Non-Hodgkin's Lymphoma
Intervention: Drug: T-cell therapy + Rituximab + IL-2
2 Recruiting Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
Conditions: CD19+ Diffuse Large B-cell Lymphomas;   Follicular Lymphomas;   Mantle Cell Lymphomas
Intervention: Drug: Pembrolizumab
3 Recruiting Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Lymphoma
Intervention: Combination Product: Drugs and Anti-CD19-CAR transduced T cells
4 Recruiting CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
Conditions: Leukemia;   Lymphoma
Intervention: Biological: CD19-directed CAR-T cells
5 Recruiting Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia;   Lymphoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-CD19-CAR transduced T cells
6 Recruiting Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Breast Carcinoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: ROR1 CAR-specific Autologous T-Lymphocytes
7 Recruiting T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Conditions: Lymphoma, Large-Cell, Anaplasitc;   Hodgkin Disease;   Lymphoma, Hodgkins;   Enteropathy-Associated T-Cell Lymphoma;   Lymphoma, Extranodal NK-T-Cell
Interventions: Biological: Anti-CD30-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
8 Recruiting Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Third generation CAR-T cells
9 Recruiting CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphocytic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Genetic: Second generation CAR-T cells
10 Recruiting Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)
Conditions: Non-Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma;   Mantle-cell Lymphoma;   Primary Mediastinal B-cell Lymphoma
Interventions: Biological: JCAR017 single-dose schedule;   Biological: JCAR017 2-dose schedule
11 Recruiting T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Conditions: Lymphoma, B-Cell;   Lymphoma, Non-hodgkins;   Lymphoma, Hodgkins;   Leukemia, B-cell
Interventions: Biological: Anti-CD19-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
12 Recruiting Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
13 Recruiting Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Biological: anti-CD20-CAR vector-transduced autologous T cells;   Other: genetically engineered lymphocyte therapy
14 Recruiting A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Condition: T Cell Non-Hodgkin Lymphoma
Intervention: Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
15 Recruiting CART-19 Immunotherapy in Mantle Cell Lymphoma
Conditions: Hematopoietic/Lymphoid Cancer;   Non-hodgkin Lymphoma,B Cell;   Mantle Cell Lymphoma
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
16 Recruiting Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
Condition: Cutaneous T Cell Lymphoma
Intervention: Drug: dimethylfumarate
17 Recruiting A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients
Conditions: T-cell Lymphoma Adults;   Previously Untreated;   High Risk
Interventions: Drug: chemotherapy (CHOP);   Drug: chemotherapy(c-ATT)
18 Recruiting Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Condition: Leukemia
Interventions: Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide
19 Recruiting Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
Condition: Lymphoma, Extranodal NK-T-Cell
Interventions: Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Pegaspargase;   Drug: Etoposide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Prednisone;   Radiation: IMRT
20 Recruiting Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
Conditions: Adult T-cell Leukemia-Lymphoma;   ATLL
Interventions: Drug: Belinostat;   Drug: Zidovudine;   Drug: Interferon-Alfa-2b;   Drug: Pegylated Interferon-Alfa-2b

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.